Doris Vokurková
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Doris Vokurková has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- David Belada
4th Department of Internal Medicine - Hematology, University Hospital, Hradec Králové, Czech Republic
2 shared publications - Dominika Écsiová
4th Department of Internal Medicine – Hematology University Hospital Hradec Králové Hradec Králové Czech Republic
2 shared publications - Lukas Smolej
4th Department of Internal Medicine – Hematology University Hospital Hradec Králové Hradec Králové Czech Republic
2 shared publications - Martin Šimkovič
4th Department of Internal Medicine – Haematology, Faculty of Medicine in Hradec Králové University Hospital and Charles University in Prague Hradec Kralove Czech Republic
2 shared publications - Ondrej Soucek
Department of Clinical Immunology and Allergology, University Hospital Hradec Kralove, 50005 Hradec Kralove, Czech Republic
2 shared publications - Pavel Vodárek
4th Department of Internal Medicine – Hematology University Hospital Hradec Králové Hradec Králové Czech Republic
2 shared publications
Latest Publications
- Open Access
- 9 August 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (15) , e7399
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy
Introduction: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied.Methods: We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first‐line treatment. Fifty‐five patients were evaluated again after the treatment with CIT.Results: We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1.Conclusions: CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.
- 9 August 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (15) , e7399
Open AccessComplex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy
Introduction: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied.Methods: We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first‐line treatment. Fifty‐five patients were evaluated again after the treatment with CIT.Results: We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1.Conclusions: CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.
- 30 June 2024
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Problems of Cryobiology and Cryomedicine
- Vol. 34 (2) , 71-112
The Modern Cryobank as Key Support for Clinical Cell and Tissue Transplantation Programmes
The authors review the essential role of modern cryobanks in the development of cryotechnology before the start of the clinical cell and tissue transplantation programme and in the routine support of these programmes within the legislative framework settled by the European Union directives. Two clinical programmes are presented as examples: the autologous and allogeneic haematopoietic progenitor cell (HPC) transplantation programme and the Czech national cryopreserved allogeneic vascular tissue (VT) transplantation programme supported by the cryobank of the University Hospital Hradec Králové, which is a part of the European Union Tissue Establishment registered under the codes CZ000425, CZ000426 and CZ000427. An overview of necessary approvals to be obtained before the start of clinical programmes is presented, the high quality of cryopreservation technology and high level of cryobank staff safety is demonstrated, and the crucial role of the cryobank in clinical HPC and VT transplantation programmes is highlighted.
- 30 June 2024
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Problems of Cryobiology and Cryomedicine
- Vol. 34 (2) , 71-112
The Modern Cryobank as Key Support for Clinical Cell and Tissue Transplantation Programmes
The authors review the essential role of modern cryobanks in the development of cryotechnology before the start of the clinical cell and tissue transplantation programme and in the routine support of these programmes within the legislative framework settled by the European Union directives. Two clinical programmes are presented as examples: the autologous and allogeneic haematopoietic progenitor cell (HPC) transplantation programme and the Czech national cryopreserved allogeneic vascular tissue (VT) transplantation programme supported by the cryobank of the University Hospital Hradec Králové, which is a part of the European Union Tissue Establishment registered under the codes CZ000425, CZ000426 and CZ000427. An overview of necessary approvals to be obtained before the start of clinical programmes is presented, the high quality of cryopreservation technology and high level of cryobank staff safety is demonstrated, and the crucial role of the cryobank in clinical HPC and VT transplantation programmes is highlighted.
- Open Access
- 28 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 6956-6970
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia
Background: In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively studiedMethods: We used multi‐color flow cytometry, to prospectively measure absolute and relative numbers of CD4+ and CD8+ T‐cells and their subsets in 45 patients with indolent untreated CLL, 86 patients indicated for first‐line treatment, and 34 healthy controls. In 55 patients, we analyzed the impact of CITResults: CLL patients had a significant increase in most cell populations in comparison to controls. Progression of CLL was characterized by significantly elevated counts with the exception of a lower percentage of naïve T‐cells. After treatment, the percentage of naïve T‐cells further decreased at the expense of effector memory T‐cells (TEM). In patients with indolent CLL, higher percentages of naïve CD4+ (p = 0.0026) and naïve CD8+ (p = 0.023) T‐cells were associated with a longer time to first treatment (TTFT). The elevation of CD4+ central memory T‐cells (TCM) (p = 0.27) and TEM (p = 0.003) counts and a higher percentage of CD4+ TEM (p = 0.0047), were linked with shorter TTFT. In treated patients, increased regulatory T‐cells count was associated with shorter time to next treatment (TTNT) (p = 0.042), while higher CD4+ TCM count with shorter TTNT (p = 0.035) and shorter overall survival (p = 0.041).Conclusion: Our results indicate that naïve cell depletion and CD4+ TCM and TEM increases are detrimental to CLL patients' prognosis.
- 28 November 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (6) , 6956-6970
Open AccessA comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first‐line therapy administration in patients with chronic lymphocytic leukemia
Background: In chronic lymphocytic leukemia (CLL), changes in the peripheral blood lymphocyte subsets play an important role in disease progression and infectious complications. The impact of chemoimmunotherapy (CIT) on these changes has not been extensively studiedMethods: We used multi‐color flow cytometry, to prospectively measure absolute and relative numbers of CD4+ and CD8+ T‐cells and their subsets in 45 patients with indolent untreated CLL, 86 patients indicated for first‐line treatment, and 34 healthy controls. In 55 patients, we analyzed the impact of CITResults: CLL patients had a significant increase in most cell populations in comparison to controls. Progression of CLL was characterized by significantly elevated counts with the exception of a lower percentage of naïve T‐cells. After treatment, the percentage of naïve T‐cells further decreased at the expense of effector memory T‐cells (TEM). In patients with indolent CLL, higher percentages of naïve CD4+ (p = 0.0026) and naïve CD8+ (p = 0.023) T‐cells were associated with a longer time to first treatment (TTFT). The elevation of CD4+ central memory T‐cells (TCM) (p = 0.27) and TEM (p = 0.003) counts and a higher percentage of CD4+ TEM (p = 0.0047), were linked with shorter TTFT. In treated patients, increased regulatory T‐cells count was associated with shorter time to next treatment (TTNT) (p = 0.042), while higher CD4+ TCM count with shorter TTNT (p = 0.035) and shorter overall survival (p = 0.041).Conclusion: Our results indicate that naïve cell depletion and CD4+ TCM and TEM increases are detrimental to CLL patients' prognosis.
- 25 August 2021
- Published by ACG Publications in Records of Natural Products
- Vol. 16 (2) , 188-193
Ex-vivo Immune-stimulating Activity of Scutellaria baicalensis and Its Major Flavonoids on Human Immune Cells
This study investigates the activation of human immune cells (T, B, and NK cells, and granulocytes) by the ethanolic and aqueous extracts of Scutellaria baicalensis root (SBR) and to identify the compounds responsible for such an effect. The cell activation was determined by expression of the cell surface glycoprotein CD69 (cluster of differentiation 69), as measured by flow cytometry. The content of the main flavonoids in SBR extracts was estimated by high performance liquid chromatography with a diode array detector. NK cells were substantially activated by the SBR ethanolic extract (25–200 µg/mL), whereas B cells were activated on a lower scale. NK cells were slightly activated by the SBR aqueous extract (100–200 µg/mL). Wogonoside and baicalin, two major flavonoids present in the SBR extracts, exhibited the highest activation effect on NK cells. The content of baicalin, wogonoside, and baicalein accounted for 201.2, 47.7, and 3.4 mg/g in the ethanolic extract; and for 150.4, 33.6, and 4.6 mg/g in the aqueous extract, respectively. This study shows the immune-stimulating properties of SBR extracts and identifies their active compounds. This data may support the potential utilization of SBR for strengthening the human immune system against bacterial and viral infections.
- 25 August 2021
- Published by ACG Publications in Records of Natural Products
- Vol. 16 (2) , 188-193
Ex-vivo Immune-stimulating Activity of Scutellaria baicalensis and Its Major Flavonoids on Human Immune Cells
This study investigates the activation of human immune cells (T, B, and NK cells, and granulocytes) by the ethanolic and aqueous extracts of Scutellaria baicalensis root (SBR) and to identify the compounds responsible for such an effect. The cell activation was determined by expression of the cell surface glycoprotein CD69 (cluster of differentiation 69), as measured by flow cytometry. The content of the main flavonoids in SBR extracts was estimated by high performance liquid chromatography with a diode array detector. NK cells were substantially activated by the SBR ethanolic extract (25–200 µg/mL), whereas B cells were activated on a lower scale. NK cells were slightly activated by the SBR aqueous extract (100–200 µg/mL). Wogonoside and baicalin, two major flavonoids present in the SBR extracts, exhibited the highest activation effect on NK cells. The content of baicalin, wogonoside, and baicalein accounted for 201.2, 47.7, and 3.4 mg/g in the ethanolic extract; and for 150.4, 33.6, and 4.6 mg/g in the aqueous extract, respectively. This study shows the immune-stimulating properties of SBR extracts and identifies their active compounds. This data may support the potential utilization of SBR for strengthening the human immune system against bacterial and viral infections.
- Open Access
- 1 January 2008
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 57 (4) , 589-600
CD27+ peripheral blood B-cells are a useful biodosimetric marker in vitro
The CD8(+) natural killer (NK) subpopulation has recently been identified as a fast and reliable biodosimetric indicator within human peripheral blood mononuclear cells (PBMC) in vitro. In irradiated and subsequently cultivated PBMC, a decrease of the relative number of intact CD3(-)CD8(+) lymphocytes 16 and 48 h after treatment has allowed for estimating the received dose in the range of 0 - 10 Gy and lethal/sublethal dose discrimination, respectively. Here we show that suitable biodosimeters can also be found in the peripheral blood B-cell compartment. Multiparameter flow cytometric analysis of irradiated and subsequently cultivated human PBMC revealed that both the CD27(+) and CD21(-) B-cell subpopulations can be used as biodosimeters and the CD19(+)CD27(+) lymphocytes have proved useful for retrospective determination of the received dose in the range of 0 - 6 Gy. In addition, several CD19(+) lymphocyte subsets characterized by co expression of CD21, CD27 and CD38 have been shown to bear biodosimetric potential, too. However, when important parameters like the original size within the CD19(+) compartment, its radiation-induced changes and data variation had been taken into account, the CD27(+) subpopulation proved superior to the other B-cell subpopulations and subsets. It appears that, in the dose range of 0 - 6 Gy, the relative decrease of CD27(+) B lymphocytes provides more sensitive and reliable data than that of CD8(+) NK-cells due mainly to lower data variation. In contrast to CD27(+) B cells, the proportions of CD27(+) subpopulations of T-cells were not affected by irradiation. We have also proposed a simple experimental protocol based on full blood cultivation and three-color CD27/CD3/CD19 immuno-phenotyping as a time-saving and inexpensive approach for practical biodosimetric evaluations on simple, three-to-four color flow cytometers.
- 1 January 2008
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 57 (4) , 589-600
Open AccessCD27+ peripheral blood B-cells are a useful biodosimetric marker in vitro
The CD8(+) natural killer (NK) subpopulation has recently been identified as a fast and reliable biodosimetric indicator within human peripheral blood mononuclear cells (PBMC) in vitro. In irradiated and subsequently cultivated PBMC, a decrease of the relative number of intact CD3(-)CD8(+) lymphocytes 16 and 48 h after treatment has allowed for estimating the received dose in the range of 0 - 10 Gy and lethal/sublethal dose discrimination, respectively. Here we show that suitable biodosimeters can also be found in the peripheral blood B-cell compartment. Multiparameter flow cytometric analysis of irradiated and subsequently cultivated human PBMC revealed that both the CD27(+) and CD21(-) B-cell subpopulations can be used as biodosimeters and the CD19(+)CD27(+) lymphocytes have proved useful for retrospective determination of the received dose in the range of 0 - 6 Gy. In addition, several CD19(+) lymphocyte subsets characterized by co expression of CD21, CD27 and CD38 have been shown to bear biodosimetric potential, too. However, when important parameters like the original size within the CD19(+) compartment, its radiation-induced changes and data variation had been taken into account, the CD27(+) subpopulation proved superior to the other B-cell subpopulations and subsets. It appears that, in the dose range of 0 - 6 Gy, the relative decrease of CD27(+) B lymphocytes provides more sensitive and reliable data than that of CD8(+) NK-cells due mainly to lower data variation. In contrast to CD27(+) B cells, the proportions of CD27(+) subpopulations of T-cells were not affected by irradiation. We have also proposed a simple experimental protocol based on full blood cultivation and three-color CD27/CD3/CD19 immuno-phenotyping as a time-saving and inexpensive approach for practical biodosimetric evaluations on simple, three-to-four color flow cytometers.